- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00504556
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
8. februar 2019 opdateret af: Daiichi Sankyo, Inc.
A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF).
The duration is 3 months of treatment and a 30 day follow-up visit.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
1146
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Brussels, Belgien
-
Genk, Belgien
-
-
-
-
-
Banja Luka, Bosnien-Hercegovina
-
Mostar, Bosnien-Hercegovina
-
Sarajevo, Bosnien-Hercegovina
-
Tuzla, Bosnien-Hercegovina
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Alberta, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Ontario
-
Oshawa, Ontario, Canada
-
Thunder Bay, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
Sherbrooke, Quebec, Canada
-
-
-
-
-
Antofagasta, Chile
-
Osorno, Chile
-
Santiago, Chile
-
Temuco, Chile
-
-
-
-
-
Arkhangelsk, Den Russiske Føderation
-
Barnaul, Den Russiske Føderation
-
Chelyabinsk, Den Russiske Føderation
-
Ivanovo, Den Russiske Føderation
-
Kaliningrad, Den Russiske Føderation
-
Kazan, Den Russiske Føderation
-
Kemerovo, Den Russiske Føderation
-
Krasnodar, Den Russiske Føderation
-
Krasnoyarsk, Den Russiske Føderation
-
Moscow, Den Russiske Føderation
-
N.Novgorod, Den Russiske Føderation
-
Novosibirsk, Den Russiske Føderation
-
Orenburg, Den Russiske Føderation
-
Penza, Den Russiske Føderation
-
Perm, Den Russiske Føderation
-
Rostov on Don, Den Russiske Føderation
-
Samara, Den Russiske Føderation
-
Saratov, Den Russiske Føderation
-
St. Petersburg, Den Russiske Føderation
-
Tomsk, Den Russiske Føderation
-
Tula, Den Russiske Føderation
-
Tyumen, Den Russiske Føderation
-
Volgograd, Den Russiske Føderation
-
Yaroslavl, Den Russiske Føderation
-
-
-
-
Alabama
-
Huntsville, Alabama, Forenede Stater
-
-
California
-
Anaheim, California, Forenede Stater
-
Beverly Hills, California, Forenede Stater
-
Stockton, California, Forenede Stater
-
-
Florida
-
Orlando, Florida, Forenede Stater
-
Sarasota, Florida, Forenede Stater
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater
-
Canton, Georgia, Forenede Stater
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater
-
-
Michigan
-
Cadillac, Michigan, Forenede Stater
-
-
Montana
-
Kalispell, Montana, Forenede Stater
-
-
Nebraska
-
Fremont, Nebraska, Forenede Stater
-
-
New Mexico
-
Santa Fe, New Mexico, Forenede Stater
-
-
New York
-
Albany, New York, Forenede Stater
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater
-
Pottstown, Pennsylvania, Forenede Stater
-
Sellersville, Pennsylvania, Forenede Stater
-
-
Texas
-
Dallas, Texas, Forenede Stater
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater
-
-
Washington
-
Bellevue, Washington, Forenede Stater
-
-
-
-
-
Minsk, Hviderusland
-
-
-
-
-
Daugavpils, Letland
-
Riga, Letland
-
Ventspils, Letland
-
-
-
-
-
Cordoba, Mexico
-
Guadalajara Jalisco, Mexico
-
Mexico City, Mexico
-
-
-
-
-
Chisinau, Moldova, Republikken
-
-
-
-
-
Bardejov, Slovakiet
-
Bratislava, Slovakiet
-
Kosice, Slovakiet
-
Lucenec, Slovakiet
-
Presov, Slovakiet
-
-
-
-
-
Cherkassy, Ukraine
-
Chernigov, Ukraine
-
Chernivtsy, Ukraine
-
Dnepropetrovsk, Ukraine
-
Donetsk, Ukraine
-
Ivano-Frankovsk, Ukraine
-
Kiev, Ukraine
-
Lutsk, Ukraine
-
Lviv, Ukraine
-
Odessa, Ukraine
-
Poltava, Ukraine
-
Ternopil, Ukraine
-
Vinnitsa, Ukraine
-
Zaporozhye, Ukraine
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 80 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Male or female, 18 to 80 years old.
- Able to provide written informed consent.
- Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)
- A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2
Exclusion Criteria:
- Subjects with mitral valve disease or previous valvular heart surgery
- Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin
- Known or suspected hereditary or acquired bleeding or coagulation disorder
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: 1
DU-176b 30mg tablet once daily
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Eksperimentel: 2
DU-176b 60mg once daily
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Eksperimentel: 3
DU-176b 30mg b.i.d.
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Eksperimentel: 4
DU-176b 60mg tablets two times a day
|
30mg tablet once daily
60mg tablet once daily
30mg tablet two times a day
60mg tablet two times a day
|
|
Aktiv komparator: 5
warfarin tablets
|
warfarin tablets
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adjudicated Incidence of Bleeding Events
Tidsramme: 3 months
|
Adjudicated Incidence of Bleeding Events during treatment period
|
3 months
|
|
Percent of Subjects With Liver-related Laboratory Marked Abnormalities (MA)
Tidsramme: 3 months
|
liver enzyme (ALT and/or AST) and/or bilirubin (TBL) abnormalities
|
3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Major Adverse Cardiac Events MACE)
Tidsramme: 3 months
|
MACE is defined as the composite of stroke [ischemic or hemorrhagic], Systemic embolic event (SEE), Myocardial Infarction (MI), Cardiovascular (CV) death, and hospitalization for any cardiac condition
|
3 months
|
|
Effects on Biomarker D-dimer
Tidsramme: 3 months
|
Mean (SD) change from baseline in D-dimer
|
3 months
|
|
Effects on Biomarker Prothrombin Fragments
Tidsramme: 3 months
|
Mean (SD) change from baseline in Prothrombin Fragments 1 and 2 (F1 and F2)
|
3 months
|
|
Pharmacokinetics (Cmin, Cmax) of DU-176b in Subjects Receiving DU-176b
Tidsramme: 3 months
|
Median (min, max) values of Cmin,ss; Cmax,ss
|
3 months
|
|
Pharmacokinetics (AUC) of DU-176b in Subjects Receiving DU-176b
Tidsramme: 3 months
|
Median (min, max) values of AUCss
|
3 months
|
|
Effects on Pharmacodynamic Biomarker Anti-Factor Xa Activity in Subjects Receiving DU-176b
Tidsramme: Day 28
|
Mean (SD) change from baseline in biomarker anti-Factor Xa [FXa] activity on Day 28, 1-3 hours post dose.
|
Day 28
|
|
Effects on Pharmacodynamic Biomarker (Endogenous FX Activity) in Subjects Receiving DU-176b
Tidsramme: Day 28
|
Mean (SD) change from baseline in biomarker endogenous FX activity on Day 28, 1-3 hours post dose.
|
Day 28
|
|
Effects on Pharmacodynamic Biomarker PICT Activity in Subjects Receiving DU-176b
Tidsramme: Day 28
|
Mean (SD) change from baseline in biomarker prothrombinase induced clotting time [PICT] on Day 28, 1-3 hours post dose. PICT was determined by PICT aasay which is a plasma based functional assay to determine the anticoagulant activity on FXa and FIIa inhibition. |
Day 28
|
|
Effects on Pharmacodynamic Biomarker PT in Subjects Receiving DU-176b
Tidsramme: Day 28
|
Mean (SD) change from baseline in biomarker prothrombin time (PT) on Day 28, 1-3 hours post dose.
|
Day 28
|
|
Effects on Pharmacodynamic Biomarker INR in Subjects Receiving DU-176b
Tidsramme: Day 28
|
Mean (SD) change from baseline in biomarker International Normalized Ratio (INR) on Day 28, 1-3 hours post dose.
|
Day 28
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juni 2007
Primær færdiggørelse (Faktiske)
1. juni 2008
Studieafslutning (Faktiske)
1. juni 2008
Datoer for studieregistrering
Først indsendt
18. juli 2007
Først indsendt, der opfyldte QC-kriterier
18. juli 2007
Først opslået (Skøn)
20. juli 2007
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
26. februar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. februar 2019
Sidst verificeret
1. marts 2015
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Karsygdomme
- Embolisme og trombose
- Arytmier, hjerte
- Atrieflimren
- Tromboemboli
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Proteasehæmmere
- Faktor Xa-hæmmere
- Antithrombiner
- Serinproteinasehæmmere
- Antikoagulanter
- Edoxaban
- Warfarin
Andre undersøgelses-id-numre
- DU176b-PRT018
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD-delingstidsramme
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD-delingsadgangskriterier
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .